convalescent plasma treatment for COVID-19: living meta-analysis of clinical studies

Table Graph

convalescent plasma treatment - versus standard of care - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	0.99 [0.93, 1.06]	< 1	0%	23 studies (23/-)	57.7 %	some concern	critical	moderate	crucial	-
death or transfer to ICU	1.07 [0.73, 1.57]	< 1	0%	1 study (1/-)	36.6 %	NA	not evaluable		crucial	-
deaths	0.74 [0.49, 1.13]	< 1	98%	32 studies (32/-)	91.9 %	some concern	critical	moderate	crucial	-
deaths (time to event analysis only)	0.72 [0.27, 1.94]	< 1	97%	5 studies (5/-)	74.2 %	some concern	serious	moderate	crucial	-
clinical deterioration	0.93 [0.69, 1.26]	< 1	0%	4 studies (4/-)	67.9 %	some concern	not evaluable	moderate	important	-
clinical improvement	1.24 [0.85, 1.81]	> 1	57%	5 studies (5/-)	86.3 %	some concern	serious	moderate	important	-
clinical improvement (14-day)	2.27 [0.90, 5.72]	> 1	0%	1 study (1/-)	95.9 %	NA	not evaluable		important	-
clinical improvement (28-day)	1.61 [0.69, 3.76]	> 1	74%	3 studies (3/-)	86.2 %	some concern	not evaluable	moderate	important	-
clinical improvement (7-day)	0.98 [0.27, 3.58]	> 1	0%	1 study (1/-)	48.8 %	NA	not evaluable		important	-
clinical improvement (time to event analysis only)	1.11 [0.77, 1.61]	> 1	3%	2 studies (2/-)	71.5 %	some concern	not evaluable	moderate	important	-
death or ventilation	0.98 [0.94, 1.03]	< 1	0%	5 studies (5/-)	79.2 %	some concern	not evaluable	moderate	important	-
hospital discharge	1.00 [0.94, 1.07]	> 1	0%	3 studies (3/-)	52.3 %	some concern	not evaluable	moderate	important	-
mechanical ventilation	0.82 [0.62, 1.08]	< 1	31%	6 studies (6/-)	92.4 %	some concern	serious	moderate	important	-
mechanical ventilation (time to event analysis only)	0.97 [0.62, 1.52]	< 1	0%	2 studies (2/-)	55.5 %	some concern	not evaluable	moderate	important	-
viral clearance	1.10 [0.19, 6.30]	> 1	0%	2 studies (2/-)	54.1 %	some concern	not evaluable	moderate	important	-
viral clearance by day 14	0.96 [0.77, 1.20]	> 1	0%	2 studies (2/-)	35.7 %	some concern	not evaluable	moderate	important	-
viral clearance by day 7	1.05 [0.81, 1.36]	> 1	41%	3 studies (3/-)	64.8 %	high	not evaluable	low	important	-
ICU admission	0.82 [0.35, 1.91]	< 1	0%	1 study (1/-)	67.7 %	NA	not evaluable		non important	-
safety endpoints 00
serious adverse events	1.25 [1.01, 1.56]	< 1	32%	4 studies (4/-)	2.2 %	some concern	not evaluable	moderate	important	-
adverse events	1.08 [0.86, 1.37]	< 1	0%	2 studies (2/-)	24.8 %	some concern	not evaluable	moderate	non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

convalescent plasma treatment - versus standard of care - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00